InterVenn Biosciences utilizes a proprietary high-throughput glycoproteomic interrogation platform using artificial intelligence and mass spectrometry for next-gen precision medicine. The company is working to find new solutions in ovarian, pancreatic, liver, prostate, and kidney cancer, together with applications from the Vista suite of solutions for treatment and monitoring, immune profiling, patient stratification, and disease progression.
B2B
101 to 250
N/A
N/A
Scaling Up
2017
Healthcare
Biotechnology
N/A
N/A
Production
Service
Yes
Active
Machine Learning
N/A
Software
6
1
$201M
Company was founded 2017 and it took almost 4 years (Aug 2021) to raise first external round
Interested in researching InterVenn Biosciences?
We have plenty of data and we can help. Our deal sourcing platform can help you perform more research about InterVenn Biosciences
Interested in what they do or partnership?
Learn more about how they work